Johnson & Johnson Sells Remaining Stake in Elan (JNJ)

Johnson & Johnson Sells Remaining Stake in Elan (JNJ)


Healthcare product company, Johnson & Johnson (JNJ) reported on Friday that it has sold 25.4 million shares of Elan Corp, ending its relationship with the Ireland based company..

In 2009, JNJ took a 18% stake in the biotechnology company for $1 billion to take over its development in bapineuzumab.

The drug, which was created to slow Alzheimer’s by reducing amyloid plaque buildup, did not pass its final testing.

JNJ sold back 82 million shares back to Elan on April 18, and now it has dumped its remaining stake in the company for $332.5 million.

The sale is not expected to impact JNJ’s full year earnings. The company reported that it expects to see earnings between $5.35 to $5.45 per share.

Johnson & Johnson shares were mostly flat during premarket trading Friday. The stock is up 21% YTD.

The Bottom Line
Shares of Johnson & Johnson (JNJ) have a 3.11% yield, based on Thursday’s closing price of $84.91.

Johnson & Johnson (JNJ) is not recommended at this time, holding a DARS™ Rating of 3.4 out of 5 stars.

Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.

Free Updates

Join over 100,000 investors who get the latest news from

Best Dividend Stocks

Looking for stocks that are poised for growth and pay solid dividends? Visit our list of the:

Best Dividend Stocks

Partner Center

Best CD Rates

Sitting on some extra cash and looking for the most current and profitable CD Rates?

Get The Best CD Rates

14 Day Free Trial

Earn more from your dividend portfolio within the next 14 days.

Sign Up Today